Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVela Technologies Regulatory News (VELA)

Share Price Information for Vela Technologies (VELA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0125
Bid: 0.012
Ask: 0.013
Change: 0.00 (0.00%)
Spread: 0.001 (8.333%)
Open: 0.0125
High: 0.0125
Low: 0.0125
Prev. Close: 0.0125
VELA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re. Economic Interest in AZD1656

21 Sep 2023 09:01

RNS Number : 2155N
Vela Technologies PLC
21 September 2023
 

21 September 2023

Vela Technologies plc

("Vela" or "the Company")

 

Update on Put Option for potential sale of Economic Interest in AZD1656

Further to the Company's announcements on 15 August 2023, 7 September 2023 and 8 September 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement made by Murphy Canyon Acquisition Corp. (NASDAQ: MURF) ("Murphy") that at the special meeting of stockholders held yesterday, its initial business combination with Conduit Pharmaceuticals Limited ("Conduit") has been approved.

 

An extract of the Murphy announcement is set out below and a link to the announcement can be found here:

 

https://www.accesswire.com/786091/murphy-canyon-acquisition-corp-announces-stockholder-approval-of-the-proposed-combination-with-conduit-pharmaceuticals-limited

 

On 20 April 2023, Vela announced that the Company entered into a put option agreement to give the Company the right, but not the obligation ("the Option"), to sell its economic interest in the commercialisation of the Covid-19 application of AZD1656 for a total consideration of £4.0 million. The Option was granted by Conduit and its prospective parent company, Murphy, a Company listed on NASDAQ.

 

On 15 May 2023, Vela announced that Murphy had filed the Form S-4 Registration Statement and preliminary proxy statement with the SEC.

 

Following the approval of the business combination of Conduit and Murphy by Murphy shareholders, the Board of Vela intends to exercise the Option following the satisfaction or waiver of the remaining closing conditions as stated in the Murphy announcement.

 

The Company will release further announcements as and when appropriate.

 

Extract from Murphy announcement

 

SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (Nasdaq:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company will operate as Conduit Pharmaceuticals Inc. and its common stock and public warrants will trade on The Nasdaq Global Market under the symbols "CDT" and "CDTTW". Assuming that closing is completed on September 21, 2023, trading in the common stock and public warrants is expected to continue on Nasdaq, switching from the symbols "MURF" and "MURFW" to the new symbols "CDT" and "CDTTW", respectively, at the open of trading on September 22, 2023.

 

About Conduit

 

Conduit is a disease agnostic life science company providing an efficient model for compound development. Formed in 2019, Conduit is a departure from the traditional big pharma/biotech business model whereby, typically companies shepherd their assets through regulatory approval, Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Conduit is led by a highly experienced team of pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, and was established to fund the development of clinical molecules licensed from major pharmaceutical companies.

 

About Murphy Canyon Acquisition Corp.

 

Murphy Canyon is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Management is led by Jack Heilbron, Chief Executive Officer and Chairman of the Board of Directors. Murphy Canyon is sponsored by Murphy Canyon Acquisition Sponsor, LLC, a wholly owned subsidiary of Presidio Property Trust, Inc. (Nasdaq: SQFT), which is expected to own 4,015,250 shares of Conduit after the successful completion of the Business Combination.

 

Important Information and Where to Find It

 

This press release relates to a proposed transaction between Conduit and MURF. In connection with the proposed Business Combination, Murphy Canyon filed its registration statement on Form S-4 that includes a proxy statement with respect to the stockholder meeting of Murphy Canyon and a prospectus with respect to securities of the combined company (the "Registration Statement"). The proxy statement/prospectus was sent to all Murphy Canyon stockholders. Murphy Canyon has also filed prospectus supplements amending the proxy statement/prospectus that was sent to all Murphy Canyon stockholders. Murphy Canyon has filed and will file other documents regarding the proposed Business Combination with the U.S. Securities and Exchange Commission (the "SEC"). INVESTORS AND SECURITIES HOLDERS OF MURPHY CANYON ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, PROSPECTUS SUPPLEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION.

 

Investors and securities holders are able to obtain free copies of the Registration Statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Murphy Canyon through the website maintained by the SEC at https://sec.gov/. In addition, the documents filed by Murphy Canyon may be obtained free of charge from Murphy Canyon's website at https://murphycanyonac.com or by written request to info@murphycanyonac.com. Additional information about the business combination agreement dated November 8, 2022, as amended (the "Business Combination Agreement"), and the transactions contemplated thereby (the "Transaction") and investor presentations, were provided in Current Reports on Form 8-K filed by Murphy Canyon with the SEC which can be accessed at www.sec.gov as well as online at https://murphycanyonac.com.

 

 

 

For further information, please contact:

Vela Technologies plc

Brent Fitzpatrick, Non-Executive Chairman

James Normand, Executive Director

Tel: +44 (0) 7410 886830

 

Allenby Capital Limited (Nominated Adviser)

Tel: +44 (0) 20 3328 5656

Nick Athanas / Piers Shimwell

Peterhouse Capital Limited (Broker)

Tel: +44 (0) 20 7469 0930

Lucy Williams / Duncan Vasey

Novus Communications (PR and IR Adviser)

Tel: +44 (0) 20 7448 9839

Alan Green / Jacqueline Briscoe

 

About Vela Technologies

Vela Technologies plc (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. Vela Technologies will also invest in already-listed companies where valuations offer additional opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGRGDCRUDDGXB
Date   Source Headline
21st Nov 20172:38 pmRNSPartial sale of holding in BTL Group Ltd
6th Nov 20172:46 pmRNSUpdate re BTL Group Ltd
2nd Nov 201712:05 pmRNSUpdate re BTL Group Ltd
19th Oct 20173:18 pmRNSResult of AGM and Completion of Investment
18th Oct 20177:00 amRNSUpdate re BTL Group Ltd
16th Oct 20177:00 amRNSInvestment of £200,000 in THEVIBE Ltd
10th Oct 20172:42 pmRNSUpdate on investment in Portr Limited
22nd Sep 20177:00 amRNSFinal Results
30th Aug 20171:45 pmRNSUpdate re BTL Group Ltd
5th Jun 20173:08 pmRNSUpdate re BTL Group Ltd
31st May 20171:50 pmRNSFurther partial sale of holding in BTL Group Ltd
3rd May 201711:59 amRNSNon Regulatory: Update re BTL Group Ltd
26th Apr 201711:16 amRNSUpdate re Rosslyn Data and Proposed Investment
19th Apr 201710:37 amRNSFurther partial sale of holding in BTL Group Ltd
18th Apr 20173:07 pmRNSCompletion of investment in BTL Group Ltd
7th Apr 20175:34 pmRNSReplacement - Update re holding in BTL Group Ltd
7th Apr 20171:00 pmRNSUpdate re holding in BTL Group Ltd
23rd Mar 20177:00 amRNSUpdate re BTL Group and Proposed Investment
7th Mar 201710:26 amRNSFurther partial sale of holding in BTL Group Ltd
6th Mar 20172:56 pmRNSPartial sale of holding in BTL Group Ltd
17th Feb 201711:55 amRNSCompletion of Bond Issue
14th Feb 201712:28 pmRNSUpdate re BTL Group Ltd
1st Feb 20179:00 amRNSProposed Issue of £550,000 Bonds
13th Jan 201710:20 amRNSUpdate re BTL Group Ltd
11th Jan 20177:30 amRNSProposed Investment in Portr & Proposed Bond Issue
23rd Dec 20167:00 amRNSHalf-year Report
21st Dec 20164:27 pmRNSHolding(s) in Company
1st Dec 20164:06 pmRNSFurther re investment in BTL Group Ltd
15th Nov 20167:00 amRNSCompletion of investment in THEVIBE Ltd
12th Oct 201610:41 amRNSUpdate on investment in Portr Limited
4th Oct 20161:07 pmRNSDirector/PDMR Shareholding
4th Oct 20167:00 amRNSInvestment of £200,000 in THEVIBE Ltd
3rd Oct 20164:30 pmRNSCompletion of Fundraising
3rd Oct 201611:03 amRNSResult of AGM
30th Sep 20165:00 pmRNSTotal Voting Rights
26th Sep 20162:56 pmRNSResult of General Meeting
13th Sep 20165:47 pmRNSDirector/PDMR Dealing
9th Sep 20167:00 amRNSProposed Fundraising, Notice of GM and AGM
5th Sep 20167:00 amRNSFinal Results for the year ended 31 March 2016
2nd Sep 20168:40 amRNSFurther re investment in BTL Group Ltd
25th Jul 20167:00 amRNSHolding(s) in Company
21st Jul 20169:39 amRNSHolding(s) in Company
12th Jul 20161:30 pmRNSNon Regulatory: Proactive Investors interview
4th Jul 201611:15 amRNSHolding(s) in Company
27th Jun 201611:00 amRNSUpdate on investment in StreamTV Networks Inc.
27th Jun 20168:45 amRNSHolding(s) in Company
16th Jun 20168:49 amRNSHolding(s) in Company
6th Jun 20167:00 amRNSUpdate on investment in Revolve Performance
3rd Jun 20167:00 amRNSHolding(s) in Company
2nd Jun 201610:06 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.